Cell and Gene Therapy Containment
Overcoming Challenges in Cell and Gene Therapy Containment.
List view / Grid view
Overcoming Challenges in Cell and Gene Therapy Containment.
Understanding and Applying the Updated FDA Guidance: Inspection of Injectable Products for Visible Particulates.
With a growing pipeline of biologics, increase in vaccine production, and small batch sizes targeting small patient populations, there’s increasing demand for advanced manufacturing tech.
Drug-device combination products offer advantages for patients but are complex and challenging to develop. Establish a holistic approach to DDCP development and assess and manage risk throughout the process.
Selecting container closure components with confidence:A data-driven approach to Container Closure Integrity.
CPHI Milan takes place in October, covering a wide range of topics from packaging and drug delivery to integrated pharma.
Simplify your move from a vial to a prefilled syringe – lifecycle planning for containment and delivery of biologics drug products
How you can cut through complexity, gain speed and get your drug to the patient as soon as possible.
With complex processes and stringent regulatory requirements, the path to developing a combination product can be uncertain and challenging